CLINICAL TRIALS PROFILE FOR GILENYA
✉ Email this page to a colleague
All Clinical Trials for GILENYA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00670449 ↗ | An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis | Completed | Mitsubishi Tanabe Pharma Corporation | Phase 2 | 2008-04-01 | This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis. |
NCT00670449 ↗ | An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis | Completed | Novartis | Phase 2 | 2008-04-01 | This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis. |
NCT01285479 ↗ | The Gilenya Pregnancy Registry | Recruiting | Novartis Pharmaceuticals | 2011-10-15 | The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to Gilenya before (up to 8 weeks before last menstrual period) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations. | |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GILENYA
Condition Name
Clinical Trial Locations for GILENYA
Trials by Country
Clinical Trial Progress for GILENYA
Clinical Trial Phase
Clinical Trial Sponsors for GILENYA
Sponsor Name